|
ImmunoStar inc
rabbit anti-cgrp primary antibody 24 112 Rabbit Anti Cgrp Primary Antibody 24 112, supplied by ImmunoStar inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/rabbit anti-cgrp primary antibody 24 112/product/ImmunoStar inc Average 90 stars, based on 1 article reviews
rabbit anti-cgrp primary antibody 24 112 - by Bioz Stars,
2026-05
90/100 stars
|
Buy from Supplier |
|
Cell Signaling Technology Inc
rabbit anti cgrp ![]() Rabbit Anti Cgrp, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/rabbit anti cgrp/product/Cell Signaling Technology Inc Average 86 stars, based on 1 article reviews
rabbit anti cgrp - by Bioz Stars,
2026-05
86/100 stars
|
Buy from Supplier |
|
PolyPeptide Laboratories
rabbit anti-cgrp antibody ![]() Rabbit Anti Cgrp Antibody, supplied by PolyPeptide Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/rabbit anti-cgrp antibody/product/PolyPeptide Laboratories Average 90 stars, based on 1 article reviews
rabbit anti-cgrp antibody - by Bioz Stars,
2026-05
90/100 stars
|
Buy from Supplier |
|
PolyPeptide Laboratories
anticgrp antibodies (rabbit sheep polyclonal ![]() Anticgrp Antibodies (Rabbit Sheep Polyclonal, supplied by PolyPeptide Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/anticgrp antibodies (rabbit sheep polyclonal/product/PolyPeptide Laboratories Average 90 stars, based on 1 article reviews
anticgrp antibodies (rabbit sheep polyclonal - by Bioz Stars,
2026-05
90/100 stars
|
Buy from Supplier |
|
Rabbit anti-CGRP [+Biotin] Antibody, 50 ug
|
Buy from Supplier |
Image Search Results
Journal: Cell reports
Article Title: CGRP signaling links tumor-associated pain to immune evasion in oral squamous cell carcinoma
doi: 10.1016/j.celrep.2026.116994
Figure Lengend Snippet: (A and B) Representative images of OSCC tumor serial sections stained with either anti-Tubb3 (top, green outline), anti-TRPV1 (middle, red outline), or anti-CGRP (bottom, blue outline) from a patient with (A) and without (B) CGRPα + nerve innervation. Positive stains are indicated by red (TRPV1) or blue (CGRP) arrows. Tumor margins are indicated by a gray dashed line. Image magnification: 6× (left) and 40× (right). Scale bar: 200 μm. (C) Quantification of the percentage of total TRPV1 and CGRP-IR nerve area relative to total Tubb3-IR nerve area across tumor tissue sections from 23 patients with HNSCC. Density is reported as a stacked bar graph. (D) Quantification of the percentage of total CD8 T cell density per square millimeter. (E) Representative images of OSCC tumor serial sections with either a large nerve bundle and low anti-CD8 or small nerve presence and high anti-CD8 immunoreactivity. Scale bar: 150 μm. (F and G) Simple linear regressions were run between patient-reported pain, percentage of total CGRP-IR nerve area relative to total Tubb3-IR, and CD8 + T cell density relative to tumor area. Pain was measured by the FACT-HN additional question 12, “I have pain in my mouth, throat or neck” (FACT-HN10). The response to this question is rated on a scale of 0 (not at all) to 4 (very much). Spearman correlation r coefficients are listed on each graph; p < 0.05. Patient demographics are located in .
Article Snippet:
Techniques: Staining
Journal: Cell reports
Article Title: CGRP signaling links tumor-associated pain to immune evasion in oral squamous cell carcinoma
doi: 10.1016/j.celrep.2026.116994
Figure Lengend Snippet: (A) Representative images of CGRP-IR in 300 μm optically cleared sagittal tongue sections from naive (left), MOC1 (middle), and MOC2 (right) tumor-bearing mice (10× magnification stitch, full focus z stack). Scale bar: 0.5 mm. (B) Representative images of co-staining with anti-CGRP and the pan-neuronal marker PGP9.5 in a 20 μm sagittal tongue section to demonstrate CGRP antibody specificity. Scale bar: 50 μm. (C) Representative images of neurite outgrowth in dissociated TG neurons in response to 24 h incubation in cell culture medium, MOC2 CM, or MOC2 medium + 1 μM anti-NGF monoclonal antibody (αNGF). A TG from one mouse was used for each treatment group, and the experiment was replicated five times ( n = 3 males, 2 females). For analysis, dissociated neurons were stained with anti-Tubb3 to visualize neurites and anti-NeuN to visualize cell bodies. Scale bar: 50 μm. (D–F) Integrative density of Tubb3 + neurites relative to the number of cell bodies in each field in response to medium and CM with or without αNGF; 12 areas of each chamber were imaged under 20× magnification, and analysis was completed within cell culture type (i.e., PEK, MOC1, and MOC2). Data are represented as mean ± SEM. One-way ANOVA; * p < 0.05, ** p < 0.01, *** p < 0.005, **** p < 0.001.
Article Snippet:
Techniques: Staining, Marker, Incubation, Cell Culture
Journal: Cell reports
Article Title: CGRP signaling links tumor-associated pain to immune evasion in oral squamous cell carcinoma
doi: 10.1016/j.celrep.2026.116994
Figure Lengend Snippet: (A) Representative image of a coronal tongue section from non-tumor bearing mice 1 week following treatment with vehicle (top) or RTX (bottom), stained with anti-CGRP to demonstrate loss of CGRP-expressing fibers following RTX treatment. Scale bar: 100 μm. (B) Schematic of the trigeminal CGRP release assay. (C) CGRP protein quantification in TG isolated from mice 1 week after RTX injection into the tongue ( n = 5 F/group). Data are represented as mean ± SEM. Independent t test, ** p < 0.01. (D) Representative ATF3 staining of in TRPV1-IR neurons in the trigeminal mandibular branch in TG sections from vehicle- and RTX-treated mice. Scale bar: 50 μm. (E) Percentage of ATF3 + TRPV1 + neurons relative to total TRPV1 + neurons in the V3 region from across 9 sections/mouse of mice treated with vehicle or RTX ( n = 3 vehicle, 4 RTX). Tissue was collected 7 days after treatment. There was no difference in the number of TRPV1 neurons between groups. Data are represented as mean ± SEM. Independent t test, *** p < 0.005. (F) RTX treatment did not affect body weight compared to vehicle-treated mice. Change in body weight was calculated as (post-treatment day 7) – (weight on first day of treatment). Independent t test. (G) Representative H&E-stained 5 μm tongue sections from vehicle- and RTX-treated mice 21 days after treatment. The tumor boundary is indicated by a black dashed line. Scale bar: 1 mm. (H) MOC1 tumor volume between groups over time ( n = 5 F/group). Data are represented as mean ± SEM. two-way ANOVA, * p < 0.05. (I and J) Example dot plots and quantification of CD3 + T cell subtype, CD19 + B cells, and NK1.1 + natural killer (NK) cells between groups ( n = 3 F/group). Within-subtype t test comparison, **** p < 0.0001.
Article Snippet:
Techniques: Staining, Expressing, Release Assay, Isolation, Injection, Comparison